Andrew P Rasdal - Net Worth and Insider Trading
Andrew P Rasdal Net Worth
The estimated net worth of Andrew P Rasdal is at least $4 Million dollars as of 2024-12-27. Andrew P Rasdal is the President & CEO of DexCom Inc and owns about 47,104 shares of DexCom Inc (DXCM) stock worth over $4 Million. Andrew P Rasdal is also the Exec Chairman of the Board of Obalon Therapeutics Inc and owns about 25,964 shares of Obalon Therapeutics Inc (OBLN) stock worth over $79,190. Details can be seen in Andrew P Rasdal's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Andrew P Rasdal has not made any transactions after 2019-08-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Andrew P Rasdal
Andrew P Rasdal Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Andrew P Rasdal owns 3 companies in total, including Obalon Therapeutics Inc (OBLN) , DexCom Inc (DXCM) , and Reshape Lifesciences Inc (RSLS) .
Click here to see the complete history of Andrew P Rasdal’s form 4 insider trades.
Insider Ownership Summary of Andrew P Rasdal
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
OBLN | Obalon Therapeutics Inc | 2020-06-23 | director & President & CEO & Exec Chairman |
DXCM | DexCom Inc | 2006-05-02 | director & President and CEO |
RSLS | Reshape Lifesciences Inc | 2016-10-05 | director & President & CEO |
Andrew P Rasdal Latest Holdings Summary
Andrew P Rasdal currently owns a total of 2 stocks. Among these stocks, Andrew P Rasdal owns 47,104 shares of DexCom Inc (DXCM) as of May 2, 2006, with a value of $4 Million and a weighting of 97.96%. Andrew P Rasdal also owns 25,964 shares of Obalon Therapeutics Inc (OBLN) as of August 6, 2019, with a value of $79,190 and a weighting of 2.04%.
Latest Holdings of Andrew P Rasdal
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
DXCM | DexCom Inc | 2006-05-02 | 47,104 | 80.57 | 3,795,169 |
OBLN | Obalon Therapeutics Inc | 2019-08-06 | 25,964 | 3.05 | 79,190 |
Holding Weightings of Andrew P Rasdal
Andrew P Rasdal Form 4 Trading Tracker
According to the SEC Form 4 filings, Andrew P Rasdal has made a total of 0 transactions in DexCom Inc (DXCM) over the past 5 years. The most-recent trade in DexCom Inc is the sale of 2,000,000 shares on May 2, 2006, which brought Andrew P Rasdal around $3 Million.
According to the SEC Form 4 filings, Andrew P Rasdal has made a total of 0 transactions in Obalon Therapeutics Inc (OBLN) over the past 5 years. The most-recent trade in Obalon Therapeutics Inc is the acquisition of 4,167 shares on August 6, 2019, which cost Andrew P Rasdal around $50,000.
Insider Trading History of Andrew P Rasdal
- 1
Andrew P Rasdal Trading Performance
GuruFocus tracks the stock performance after each of Andrew P Rasdal's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Andrew P Rasdal is -43.38%. GuruFocus also compares Andrew P Rasdal's trading performance to market benchmark return within the same time period. The performance of stocks bought by Andrew P Rasdal within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Andrew P Rasdal's insider trading performs compared to the benchmark.
Performance of Andrew P Rasdal
Andrew P Rasdal Ownership Network
Andrew P Rasdal Owned Company Details
What does Obalon Therapeutics Inc do?
Who are the key executives at Obalon Therapeutics Inc?
Andrew P Rasdal is the director & President & CEO & Exec Chairman of Obalon Therapeutics Inc. Other key executives at Obalon Therapeutics Inc include Chief Financial Officer Nooshin Hussainy , Chief Technology Officer Mark Brister , and Chief Retail Officer Robert J Macdonald .
Obalon Therapeutics Inc (OBLN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Obalon Therapeutics Inc (OBLN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Obalon Therapeutics Inc (OBLN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Obalon Therapeutics Inc (OBLN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Obalon Therapeutics Inc Insider Transactions
Andrew P Rasdal Mailing Address
Above is the net worth, insider trading, and ownership report for Andrew P Rasdal. You might contact Andrew P Rasdal via mailing address: C/o Dexcom, Inc., 5555 Oberlin Drive, San Diego Ca 92121.